This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
New Strong Buy Stocks for May 28th
by Zacks Equity Research
PHIO, FLNG, BWB, ALRS and HALO have been added to the Zacks Rank #1 (Strong Buy) List on May 28, 2025.
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
by Zacks Equity Research
AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
by Zacks Equity Research
GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
by Zacks Equity Research
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
by Zacks Equity Research
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
by Zacks Equity Research
The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.
ARMP Soars 72% in a Month Following Infectious Disease Study Success
by Zacks Equity Research
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
by Zacks Equity Research
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
by Zacks Equity Research
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
by Zacks Equity Research
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
by Zacks Equity Research
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme
by Zacks Equity Research
Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme have been highlighted in this Screen of The Week article.
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
by Zacks Equity Research
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
4 Stocks With Impressive Interest Coverage Ratio to Buy Now
by Sumit Singh
STRL, AXS, MOH & HALO's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
by Zacks Equity Research
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GRPM
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
by Zacks Equity Research
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025. Shares rise.
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.